Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2013 by Stanford University.
Recruitment status was Recruiting
Information provided by (Responsible Party):
First received: December 4, 2007
Last updated: October 23, 2013
Last verified: October 2013
The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.
||Observational Model: Cohort
Time Perspective: Prospective
||Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
- to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||July 2014 (Final data collection date for primary outcome measure)
Standard of care
Other Name: blood draw
The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with advanced stage NSCLC who are either newly diagnosed, or who have evidence of disease progression.
Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases):
- Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
- Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
- ability to sign informed consent
- at least 18 years of age
Inclusion Criteria (Controls):
- no known prior or active malignancy
- ability to sign informed consent
- at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years
Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years
2. pregnant women
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568282
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
|Contact: Lisa Zhou 650-736-4112 email@example.com |
|Contact: Cancer Clinical Trials Office (650) 498-7061 |
|Principal Investigator: Heather A. Wakelee |
|Sub-Investigator: Dr Jessica S. Donington |
||Heather A. Wakelee
No publications provided
History of Changes
|Other Study ID Numbers:
||LUN0017, 96710, LUN0017, 4086
|Study First Received:
||December 4, 2007
||October 23, 2013
||United States: Food and Drug Administration
United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 09, 2015
Neoplastic Cells, Circulating
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms